Harvest Investment Services, LLC Altimmune, Inc. Transaction History

Harvest Investment Services, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$8.69 - $12.48 $99,900 - $143,470	-11,496 Closed	0 $0
Q3 2021 Oct 29, 2021	SELL	$8.43 - $16.81 $4,434 - $8,842	-526 Reduced 4.38%	11,496 $130,000
Q2 2021 Aug 10, 2021	SELL	$9.85 - $16.46 $6,727 - $11,242	-683 Reduced 5.38%	12,022 $118,000
Q1 2021 May 06, 2021	BUY	$12.71 - $24.31 $31,724 - $60,677	2,496 Added 24.45%	12,705 $179,000
Q4 2020 Feb 01, 2021	SELL	$7.84 - $14.22 $34,793 - $63,108	-4,438 Reduced 30.3%	10,209 $115,000

Q3 2020 Oct 29, 2020	BUY	$9.93 - $33.26 $145,444 - $487,159	14,647 New	14,647 $193,000

185

44.4M

1.1M

647K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $325M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Harvest Investment Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Harvest Investment Services, LLC with notifications on news.